Overview

A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf 50 mg venlafaxine hydrochloride tablets with Wyeth Pharmaceuticals (Effexor®) 50 mg venlafaxine (as venlafaxine hydrochloride) tablets under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Venlafaxine Hydrochloride